CN103446147A - Application of Lycojaponicumin C in cervical cancer treatment drug - Google Patents
Application of Lycojaponicumin C in cervical cancer treatment drug Download PDFInfo
- Publication number
- CN103446147A CN103446147A CN2013104370183A CN201310437018A CN103446147A CN 103446147 A CN103446147 A CN 103446147A CN 2013104370183 A CN2013104370183 A CN 2013104370183A CN 201310437018 A CN201310437018 A CN 201310437018A CN 103446147 A CN103446147 A CN 103446147A
- Authority
- CN
- China
- Prior art keywords
- lycojaponicumin
- cervical cancer
- application
- preparation
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Lycojaponicumin C in preparation of a cervical cancer treatment drug and belongs to the technical field of novel medicine application. Evaluation of in-vitro thiazolyl blue (MTT) anti-tumor activity shows that the Lycojaponicumin C also has remarkable inhabiting effect on growth of human cervical cancer cell strains HeLa, HeLa229, HCE1 and CaSKi. Therefore, the Lycojaponicumin C can be used for preparation of an anti-cervical cancer drug and has good development and application prospect. The application of the Lycojaponicumin C in the preparation of the cervical cancer treatment drug is disclosed for the first time. The skeleton type is a novel skeleton type, and the high cervical cancer cell inhibiting activity of the Lycojaponicumin C is previously unimagined.
Description
Technical field
The present invention relates to the new purposes of compound L ycojaponicumin C, relate in particular to the application of Lycojaponicumin C in preparing medicament for resisting cervical cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be the natural product or derivatives thereof, as paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, searching anticancer compound or lead compound have great importance.
The compound L ycojaponicumin C the present invention relates to is one and within 2012, delivers (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum.Organic Letters14 (10), 2614-2617.) New skeleton compound, this compound has brand-new framework types, purposes for the Lycojaponicumin C the present invention relates in preparation treatment cervical cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for cervical cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound L ycojaponicumin C in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Lycojaponicumin C in preparing medicament for resisting cervical cancer, and the structural formula of Lycojaponicumin C is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Lycojaponicumin C also has significant inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 1.24 ± 0.13 μ M, 1.25 ± 0.12 μ M, 2.21 ± 0.19 μ M and 1.19 ± 0.16 μ M.Therefore, Lycojaponicumin C can, for the preparation of medicament for resisting cervical cancer, have good development prospect.
The purposes of the Lycojaponicumin C the present invention relates in preparation treatment cervical cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for cervical cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound L ycojaponicumin C involved in the present invention is referring to document (Wang, X.J.et al., 2012.Lycojaponicumins A-C, Three Alkaloids with an Unprecedented Skeleton from Lycopodium japonicum.Organic Letters14 (10), 2614-2617.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycojaponicumin C tablet involved in the present invention:
Get 20 and digest compound Lycojaponicumin C, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound L ycojaponicumin C capsule involved in the present invention:
Get 20 and digest compound Lycojaponicumin C, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Lycojaponicumin C to human cervical carcinoma cell lines
1. method: in the cell of growth logarithmic (log) phase: Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4the concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that the drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Lycojaponicumin C of 0.01 μ M and 0.001 μ M.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Lycojaponicumin C has significant inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi.This compound suppresses the IC of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi growth
50value is respectively: 1.24 ± 0.13 μ M, 1.25 ± 0.12 μ M, 2.21 ± 0.19 μ M and 1.19 ± 0.16 μ M.
By above-described embodiment, shown, Lycojaponicumin C of the present invention has good inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi.Prove thus, Lycojaponicumin C of the present invention has the anti-cervical cancer activity, can be for the preparation of medicament for resisting cervical cancer.
Claims (1)
1.Lycojaponicumin the application of C in treatment cervical cancer medicine, described compound L ycojaponicumin C-structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310437018.3A CN103446147B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310437018.3A CN103446147B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446147A true CN103446147A (en) | 2013-12-18 |
| CN103446147B CN103446147B (en) | 2015-11-25 |
Family
ID=49729268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310437018.3A Expired - Fee Related CN103446147B (en) | 2013-09-23 | 2013-09-23 | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446147B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
-
2013
- 2013-09-23 CN CN201310437018.3A patent/CN103446147B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059043A (en) * | 2011-10-24 | 2013-04-24 | 中国医学科学院药物研究所 | Clavatine A-C and preparation method as well as pharmaceutical composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446147B (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN103446147A (en) | Application of Lycojaponicumin C in cervical cancer treatment drug | |
| CN103446141A (en) | Application of Lycojaponicumin C in tongue cancer treatment drug | |
| CN103479632A (en) | Application of Lycojaponicumin B in preparation of drugs for treating cervical carcinoma | |
| CN103446133A (en) | Application of Lycojaponicumin B in tongue cancer treatment drug | |
| CN103446123A (en) | Application of Lycojaponicumin B in colorectal cancer treatment drug | |
| CN103479633A (en) | Application of Lycojaponicumin B in preparation of drugs for treating nasopharyngeal carcinoma | |
| CN103446143A (en) | Application of Lycojaponicumin C in gastric cancer treatment drug | |
| CN103463052A (en) | Application of Lycojaponicumin A in drugs for treating cervical cancer | |
| CN103463054A (en) | Application of Lycojaponicumin A in medicaments for treating bladder cancer | |
| CN103446142A (en) | Application of Lycojaponicumin C in pancreatic cancer treatment drug | |
| CN103446122A (en) | Application of Lycojaponicumin B in prostate cancer treatment drug | |
| CN103463055A (en) | Application of Lycojaponicumin B in medicine for treating endometrial cancer | |
| CN103463016A (en) | Application of Lycojaponicumin A in medicine for treating endometrial cancer | |
| CN103463051A (en) | Application of Lycojaponicumin A in medicaments for treating nasopharyngeal cancer | |
| CN103463041A (en) | Application of Lycojaponicumin B in medicine for treating bladder cancer | |
| CN103446146A (en) | Application of Lycojaponicumin C in ileocecum cancer treatment drug | |
| CN103446130A (en) | Application of Lycojaponicumin B in liver cancer treatment drug | |
| CN103463059A (en) | Application of Lycojaponicumin B in medicine for treating laryngocarcinoma | |
| CN103479630A (en) | Application of Lycojaponicumin A in preparation of drugs for treating breast cancer | |
| CN103494812A (en) | Application of Lycojaponicumin A in drug for treating ovarian cancer | |
| CN103446144A (en) | Application of Lycojaponicumin C in biliary duct cancer treatment drug | |
| CN103446128A (en) | Application of Lycojaponicumin B in skin cancer treatment drug | |
| CN103446092A (en) | Application of Incarviatone A in cervical cancer treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Jinghong Inventor after: Li Jinghong, Jing Xiang Bao Inventor before: Wu Junhua Inventor before: Huang Rong |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150930 Address after: 262199, Shandong, Weifang Province, Yongan Road, No. 9, building 1, unit 402, Anqiu, Shandong Anqiu Hospital of traditional Chinese medicine, 250 Applicant after: Li Jinghong Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20190923 |